FDA grants RPD designation to Quoin's QRX003 for PSS
Analysis based on 10 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The RPD designation enhances Quoin's regulatory and commercial prospects for QRX003, potentially adding significant non-dilutive value through PRVs. This positive regulatory milestone is likely to support Quoin's stock price and investor sentiment in the near term.
On September 8, 2026, the U.S. United States — Food and Drug Administration granted Rare Pediatric Disease (RPD) Designation to Quoin Pharmaceuticals' lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). This is the second RPD designation for QRX003, following a prior designation for Netherton Syndrome. The designation makes Quoin eligible to receive a Priority Review Voucher (PRV) upon approval of a New Drug Application for QRX003 for PSS, potentially yielding two PRVs with an aggregate non-dilutive cash value exceeding $300 million based on current trading values. Quoin expects to initiate a Phase 2 clinical study in the second half of 2026, enrolling up to 12 pediatric and adult PSS patients in the U.S. and Europe. There are currently no approved treatments for PSS, a rare autosomal recessive skin disorder caused by CDSN gene variants.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard